| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
|
J Clin Oncol
|
2003
|
17.67
|
|
2
|
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
|
Blood
|
2009
|
15.95
|
|
3
|
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
|
Haematologica
|
2008
|
2.32
|
|
4
|
The myth of the second remission of acute leukemia in the adult.
|
Blood
|
2012
|
2.26
|
|
5
|
Treatment of relapsed and refractory acute myelogenous leukemia.
|
Leukemia
|
2000
|
1.79
|
|
6
|
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
|
J Clin Oncol
|
2013
|
1.66
|
|
7
|
Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia.
|
J Clin Oncol
|
2004
|
1.02
|
|
8
|
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
|
Ann Hematol
|
2003
|
0.96
|
|
9
|
IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
|
Am J Ther
|
2006
|
0.92
|
|
10
|
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
|
Leuk Res
|
2002
|
0.82
|
|
11
|
Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.
|
Stem Cell Investig
|
2017
|
0.75
|
|
12
|
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
|
Br J Haematol
|
2016
|
0.75
|
|
13
|
Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
|
Am J Hematol
|
2009
|
0.75
|